Any minute now, next news we will hear is NKTR 102. I am so over NKTR 118.
if NKTR gave all right back to AZN , nktr pps would go back up. What I hope is the data presented and a FDA decision on next steps.
Flat out approval. It is rare for a Cancer drug to have a Phase III breast cancer trial ongoing Ovarian cancer trial and be at a point when Phase IIA patient with long term data supported with another Phase IIB trial for a second indication or is that in reverse. Ovarian Cancer is the 1st Cancer indication for NKTR 102.
If NKTR 102 gets approval for Ovarian cancer, the Phase II Breast cancer can be used to sell off label.
So I can see the FDA doing a lot of thinking here. What to do. I bet FDA makes NKTR continue Phase III for Breast cancer and approves Ovarian cancer Phase IIB.
I can also see the FDA holding Phase IIB data until Phase III Breast cancer is completed. for bot indications.
I see this as most likely. Whether now or within 6-9 months. NKTR 102 wll drive NKetar to 700PPs....